Avastin, the anti-cancer drug already widely used off-label by physicians to treat the wet form of age-related macular degeneration, is as effective as Lucentis, the gold standard for treatment of ...

One of two Phase III studies of the drug Lucentis in patiets with diabetic macular edema met its goal, according to Genentech Inc. One of two Phase III studies of the drug Lucentis in patiets with ...

Lucentis, which is used to treat certain eye conditions, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

In DME, respondents use Lucentis in 44% and, despite lack of FDA approval for treating that condition, the specialists said they expect Eylea to erode Lucentis DME share by a third to 29%. In the US, ...

Two popular drugs used to treat age-related macular degeneration (AMD) appear to be equally effective in improving vision, according to a new study. The difference? One costs $2,000 per dose, but ...

Additionally, prescribing Lucentis offers a benefit for physicians, as Medicare reimburses them the price of the drug plus six percent, according to the report. Obviously, 6 percent of $50 is ...

Lucentis is not approved as a treatment for macular edema. But it is approved for another eye disease, age-related macular degeneration. So doctors can — and some already do — use the drug off ...

Both sides in a debate over eye treatment took solace from a study that said Genentech drugs Lucentis and Avastin are equally effective in the eye but Avastin had a slightly higher rate of serious ...

Ranibizumab, more commonly known by its brand name Lucentis, is delivered as an injection to the eye and runs about $2,023 per dose. Many patients require up to 12 injections per year.

FDA approves Coherus’ Cimerli™ (ranibizumab-eqrn) as the First and only interchangeable biosimilar to Lucentis ® for all five indications, with 12 months of interchangeability exclusivity ...

As expected, the FDA on Friday gave its approval to Genentech to market Lucentis for wet, age-related macular degeneration. Genentech says it plans to charge $1,950 a dose for the drug, which will ...

Lucentis is not known to interact with other medications, herbs, supplements, foods, or alcohol. The drug’s manufacturer didn’t look at interactions in clinical trials of Lucentis.